Contract research and manufacturing company AMRI acquired Whitehouse Laboratories, which provides testing services, including chemical and material analysis, method development and validation, and quality control verification services to the pharma, medical device, and personal care industries. The cost of the deal was $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.

“With the proliferation of ever-tightening standards in the life sciences sector and mounting concern regarding quality and safety of pharmaceutical products and medical devices, Whitehouse Labs meets the increasingly complex needs of customers we service and will augment our discovery, development, and manufacturing services nicely,” said William Marth, AMRI’s president and CEO.

“Favorable dynamics are increasing the trend among biopharmaceutical manufacturers to outsource testing services and our capabilities in analytical testing and diverse client base are highly complementary to AMRI,” added Brian Mulhall, co-founder of Whitehouse Labs.

Previous articleStopping Premature Protein Synthesis Halts Genetic Diseases
Next articleNeuronal Death Is Possible Onset Source of Multiple Sclerosis